Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6221633 | SANOFI AVENTIS US | Insulin derivatives having a rapid onset of action |
Jun, 2018
(5 years ago) | |
US7452860 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Mar, 2022
(2 years ago) | |
US7696162 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Mar, 2022
(2 years ago) | |
US6960561 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Jan, 2023
(1 year, 3 months ago) | |
US8603044 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
US9827379 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
US9233211 | SANOFI AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(2 months ago) | |
US9775954 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
US9610409 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
US9604008 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
US9526844 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
US9408979 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(2 months ago) | |
US8556864 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
US9011391 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(a month ago) | |
US8992486 | SANOFI AVENTIS US | Pen-type injector |
Jun, 2024
(a month from now) | |
US9604009 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
US9533105 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
US9623189 | SANOFI AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
US9561331 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
US8512297 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2024
(4 months from now) | |
US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(11 months from now) | |
US7918833 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
US9717852 | SANOFI AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) |
Apidra Solostar is owned by Sanofi Aventis Us.
Apidra Solostar contains Insulin Glulisine Recombinant.
Apidra Solostar has a total of 23 drug patents out of which 14 drug patents have expired.
Expired drug patents of Apidra Solostar are:
Apidra Solostar was authorised for market use on 16 April, 2004.
Apidra Solostar is available in injectable;subcutaneous dosage forms.
Apidra Solostar can be used as improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve, improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve, method of treating a patient suffering from diabetes mellitus.
The generics of Apidra Solostar are possible to be released after 08 April, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: Method of treating a patient suffering from diabetes mellitus; Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glyce...
Dosage: INJECTABLE;SUBCUTANEOUS